Search Articles
WILMINGTON, Del – Shareholders want the $3.6 billion “coercive” sale of Human Genome Sciences to GlaxoSmithKline enjoined until they have time to read the lengthy offering statements, in a federal class action.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.